baxter report solid outlook match
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
baxter face number near-term challeng follow
spin-off baxalta think growth remain rel
stabl go forward manag attempt boost
profit lower close peer like
freseniu hospira acquir carefus acquir
becton dickinson thank compani competit
advantag dialysi hospit market give decent
odd margin expans gain come year
number factor depress baxter histor cash flow
recent better-than-expect margin expans effort offer
evid futur profit gain gener competit
brand oncolog drug cyclophosphamid end
currenc headwind dis-synergi baxalta split
regulatori manufactur issu pension expens
adjust weigh histor earn beyond
mostli temporari issu think manag restructur
effort continu improv profit thank synergi
gambro acquisit optim manufactur
distribut oper exit unprofit busi line
refocus new product launch higher-margin segment
nutrit anesthet biosurgeri meanwhil capit
expenditur declin compani work
regulatori issu expand manufactur capac
emerging-market exposur healthi demand mani
long-term growth baxter compani sale
intern market emerg market make
impress sale nearli one third new baxter revenu
renal segment particularli expos intern
market boost compani growth trajectori thank
rise global rate diabet obes high blood pressur
increas global demand dialysi sustain strong dialysi
market growth especi true baxter periton
dialysi oper global market clinic infrastructur
typic match unit state europ
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
busi segment renal segment sale includ hemodialysi
periton dialysi product acut therapi sale also
focus near-term kidney issu patient medic deliveri
sale includ iv pump solut pharmaceut sale
consist primarili inject drug anesthet gase compound
servic nutrit sale includ parenter nutrit therapi
advanc surgeri sale mostli incorpor hemostasi product
biosurg sealant contract manufactur servic round
roughli remain sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
baxter report solid outlook match
constant-curr growth adjust
oper margin basi point last
year fourth quarter baxter end fiscal
slightli ahead expect compani
outlook constant-curr revenu growth
adjust oper margin fall near
forecast therefor dont anticip major chang
fair valu estim updat model
baxter still linger issu deal
clari warn
letter on-going pressur
cyclophosphamid still encourag underli
perform busi new product innov
remain headwind pharmaceut divis
expect mid-single-digit growth baxter
segment leav narrow moat rate
baxter clinic nutrit medic deliveri
segment fell slightli forecast fourth
quarter strong result pharmaceut advanc
surgeri segment kept overal growth larg step
expect clinic nutrit medic
deliveri segment neg flat constant-
currenc sale respect continu face linger
effect note previou quarter suppli disrupt
relat hurrican maria expect perform
gradual improv segment especi
compani face easier year-over-year comparison
manag also note longer sale cycl infus
pump custom delay purchas even though baxter
believ gain increment share
baxter segment sale better expect
pharmaceut segment growth benefit new
product launch healthi demand anesthesia
compound servic anticip competit
cyclophosphamid brevibloc sale
million respect quarter like make
quarter segment growth difficult sustain
temporari benefit competitor suppli constraint help
boost growth recothrom lead growth
advanc surgeri lastli renal segment sale growth
match expect manag note high-
single-digit pd growth unit state off-set
declin sale less profit blood line product
result baxter focu profit busi
rais fair valu estim baxter per
share rais long-term margin outlook
still somewhat skeptic manag ambiti goal
reach adjust oper margin
recent result on-going busi develop
effort suggest longer runway exist previous
profit low end long-term plan fair
think baxter long-term revenu growth potenti
near organ constant-curr basi led larg
higher growth opportun renal nutrit
biosurgeri segment togeth constitut nearli
consolid revenu expect low- mid-single-digit
growth baxter segment addit
focus higher-growth segment new product
launch baxter intern emerging-market
exposur support compani long-term growth outlook
baxter move beyond recent temporari headwind
think manag focu control cost
boost profit aspect busi lead
nearli basi point margin expans next
five year forecast lead adjust
oper margin close gener competit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
segment lead averag annual growth almost
also forecast manag exceed initi
cost-sav estim streamlin manufactur
distribut effort success transit
growth factor push adjust oper margin
nearli basi point base-cas
forecast return capit eventu climb
scenario impli fair valu estim per
fair valu estim per share bear-cas
forecast incorpor slower growth less margin
expans greater market competit less price
power keep growth report segment
low-single-digit addit forecast manag
fall well margin expans goal adjust
oper margin reach return capit
remain near midteen scenario
think economi scale support narrow moat
baxter modest switch cost baxter
segment like infus pump anesthet dialysi
consider diversif follow baxalta spin-off
think retain suffici exposur varieti
oligopolist med tech market fairli high barrier
entri -- due larg up-front capit cost achiev
necessari scale regulatori requir -- diminish
oper risk sustain return cost
capit substanti portion compani sale come
commodifi product dialysi solut
dialyz inject drug iv solut offer
littl price power leav us hesit award wide
econom moat rate time
think approxim baxter oper
measur revenu hemodialysi periton dialysi
cyclophosphamid sale nearli
million larg headwind profit
sinc manag focu higher margin
market improv oper effici led
consist improv profit also think
capit spend percentag sale fall
expand solut
manufactur capac draw close
profit combin lower capit spend
push free cash flow close billion
estim assumpt result return capit
recov estim baxter cost
capit approxim
year effort
sinc baxter fairli well diversifi particip
rel stabl healthcar market think compani
medium uncertainti rate
bull-cas scenario assum new product launch
favor price condit greater market
high-single-digit revenu growth across report
emerg market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
parenter nutrit iv pump solut biosurgeri
anesthet possess competit advantag worthi
econom moat tend view baxter
inject gener drug -- fewer competit
advantag nonetheless share signific synergi
baxter manufactur process leverag
hospit salesforc help contribut compani
baxter major player global dialysi equip
integr busi largest dialysi servic
provid equip manufactur give competit
edg baxter take second place larger
hemodialysi product market absolut domin
smaller periton market approxim
share respect estim economi scale
vital market especi manufactur
commoditylik dialysi consum like dialyz
dialysi solut acquisit gambro also
made baxter formid competitor ad extra
scale expand product catalog
global iv pump market baxter particip
concentr oligopoli includ carefus bought
hospira bought braun
freseniu infus pump long life
approxim five-year replac cycl hospit
often stick familiar brand keep switch
network softwar help devic becom
embed custom oper hospit seek lower
medic administr cost increas drug safeti
devic correspond softwar integr
hospit infrastructur transfer competit
recur revenu stream higher-margin dedic
consum hospira baxter freseniu also
among primari manufactur iv solut use
infus pump includ pump solut
estim baxter global iv market share near
baxter anesthet franchis one profit
segment thank high barrier entri strong
switch cost baxter competitor offer
supran isofluran sevofluran face gener
competit primarili piram
desfluran brand supran like soon face
gener competit patent expir late
howev complex manufactur inhal
drug along proprietari vapor hardwar instal
manufactur help keep barrier entri switch
cost higher convent drug translat
low level competit estim baxter market
share segment
think necessari economi scale product
complex support strong competit advantag
baxter parenter nutrit biosurgeri oper
among compani highest-margin segment
along anesthet similar baxter solut
higher complex
entri higher common tube-f nutrit
product surgic sealant tisseel floseal make
baxter major player biosurgeri market along
primari competitor johnson johnson baxter ad
franchis time apatech synovi
acquisit respect enhanc
bone fusion soft tissu repair capabl
think baxter larg presenc sever stabl
oligopoli major revenu base lead
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
stabl moat baxter primarili particip
predict market
evolut avoid potenti risk disrupt
biotech product spun baxalta busi new
product launch includ new dialysi infus
pump enabl baxter broaden market
offer stay ahead competit preserv price
power on-going invest boost solut
manufactur capac preserv compani
scale advantag part margin expans goal
imagin manag invest capit
moat-worthi higher-margin biosurgeri nutrit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
obaxt typic lead competitor often take
number-on -two spot mani market
compet dialysi equip parenter
nutrit biosurgeri anesthet gase
product launch refocus capit higher-
margin product line de-emphasize unprofit
segment enhanc baxter profit
oemerg market prime sourc growth
mani baxter product especi dialysi
product nutrit solut
obaxt profit appear
peer could make margin gain difficult
come year
oalthough mani baxter product essenti
medic care patient health mani
compani product similar altern
owhil baxter acquisit gambro strengthen
firm posit dialysi market gambro
histor growth flat baxter goal
acceler organ gambro-sourc growth
next year could prove lofti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
baxter retain rel good financi health follow
spin-off baxalta baxter use cash spin-off
retain stake baxalta pay debt reduc
underfund pension tender exist share long
manag continu improv profit
cash flow anticip leverag ratio improv
current expect baxter retain net debt/adjust ebitda
along comfort interest coverag ratio
manag target dividend pay-out ratio
adjust net incom share repurchas
small acquisit also like remain factor capit
adjust free
gener
gener revolv adjust
commit
presenc rel stabl healthcar market
give compani medium uncertainti rate think
baxter shed potenti riskier asset baxalta
particip market littl risk disrupt
competit threat gener competit cyclophosphamid
late drag profit sinc baxter
major patent protect drug
issu recur theme investor despit
modest likelihood futur gener competit
manufactur market barrier entri
product categori preserv baxter market share
regulatori issu remain concern busi
includ previou warn letter food drug
administr view current problem
major threat busi baxter face major
setback past howev includ colleagu
infus pump recal think poor capit alloc
compani inabl improv profit long
term may one greater risk healthi return
futur
inhal anesthet portfolio
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
almeida previous chairman ceo covidien
join baxter octob replac longtim
chairman ceo robert parkinson jr baxalta
spin-off parkinson focus invest baxter pipelin
view posit sign even though payoff
mani pipelin invest remain unclear
improv compani profit appear
almeida greatest challeng somewhat
concern issu previous
address refocus profit busi
line streamlin manufactur distribut
oper see baxter lag profit
potenti sign poor manag qualiti place
onu almeida team boost result
better-than-expect perform compani
show earli sign success manag margin
improv initi manag commit
pay rel healthi dividend baxter seem
reason imagin probabl number
extern intern invest opportun could
baxter intent expand gener inject drug
far capit alloc decis seem reason
perspect jame saccaro execut
experi baxter hill-rom becam baxter cfo
opinion fortun
ceo/chairman board/
repres date owner name posit common share held report holder issuer
america corpor
fidel manag research compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rule unconstitut district court
near-term impact fundament dec
dec judg reed connor northern district
texa issu rule effect declar patient
protect afford act
unconstitut assum littl chang
compani cover healthcar sector
near term rule like make way
appeal process surpris see
case third appear make front
 suprem court potenti timelin final
basi decis find root congress
elimin shared-respons financi penalti
accompani passag tax cut job act
late last year short judg connor found individu
mandat essenti insever provis
congress decis elimin enforc
tax penalti law render entireti
legisl unconstitut logic follow
 suprem court decis upheld
constitut congress power taxat
view healthcar provid sector at-risk
stem chang prevail healthcar
legisl whether chang individu coverag
roll-back medicaid expans higher uninsur
rate unequivoc equat pressur hospit margin
payer perspect trade-off littl less clear
although medicaid-focus insur like feel
bulk enrol loss
assumpt earli day addit wildcard
potenti legisl action muddi
ultim financi penalti carri
insur coverag set end jan
understand feder govern intend
maintain statu quo appeal process
insur alreadi lock rate propos
earliest like see potenti effect
rule premium polici offer slate
open enrol season
baxter medic nutrit segment issu
haunt firm result oct
caus problem third quarter like
becom prolong challeng compani
remedi plan lower top-lin forecast
year model current dynam doesnt
dramat shift long-term think busi
line
manag outlook therefor
expect leav fair valu estim narrow moat
rate place manag lower year-end revenu
growth forecast approxim basi point
stronger perform pharmaceut advanc
surgeri acut therapi segment drag
on-going weak medic deliveri
clinic nutrit segment lower tax rate on-going
effici effort help push year-end adjust ep
high-end manag
still
intend make chang moat rate fair
valu estim result decis continu
monitor case make way appel
court come month outcom timelin
uncertain make meaning chang
medic deliveri clinic nutrit segment
post weaker-than-expect result constant-
currenc sale declin respect
previous report issu busi
taken longer correct manag origin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
anticip led leadership chang
accord manag manag note number
custom altern competitor solut small-
volum bag unexpect inventori adjust
suppli improv large-volum bag although expect
issu wont rapidli fix still anticip
gradual recoveri segment come
baxter busi line continu perform
within expect baxter dialysi segment --
includ renal care acut therapi segment --
continu post stabl perform previou quarter
constant-curr growth respect
quarter resili cyclophosphamid sale
gain clari inject busi bolster
perform pharmaceut segment
still think acquisit play central role baxter
attempt focu busi less commodit
product categori improv overal profit base
manag commentari compani seem
evalu number acquisit opportun includ
larg busi well categori outsid baxter
core oper year unexpect weak could
make manag desper new growth
avenu may increas odd announc
sooner rather later
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
